Green Cross stock draws focus as Q3 operating profit jumps 68.5%
Published on 11/11/2026 at 00:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSProfit growth meets pipeline catalysts
- GC Biopharma improved quarterly profitability as influenza vaccines and Alyglo sales expanded.
- A Fabry disease licensing payment is expected to support fourth-quarter results.
- The company is investing in plasma-derived therapies, vaccines and global manufacturing capacity.
GC Biopharma reported a sharp improvement in third-quarter profitability on November 2, according to Seoul Economic Daily. Consolidated revenue reached KRW 522.1 billion, down 14.3 percent from a year earlier, while operating profit rose 68.5 percent to KRW 49.2 billion. Net income climbed 1,051.9 percent to KRW 208.5 billion.
Higher-margin products lift earnings
GC Biopharma attributed the operating improvement to stronger sales of its GCFlu influenza vaccine and the plasma-derived therapy Alyglo. The flu vaccine benefited from peak-season demand and revenue deferred from the second quarter. Alyglo revenue reached USD 46 million in the quarter, compared with USD 26 million a year earlier.
The net profit surge also reflected a one-time payment of about KRW 290 billion from the sale of the company's stake in Curevo to Eli Lilly. That transaction-related effect makes the bottom-line comparison less representative of recurring earnings than the operating result.
Licensing deal adds fourth-quarter catalyst
GC Biopharma expects a KRW 46.8 billion upfront payment from a global licensing agreement for a next-generation Fabry disease candidate to be booked in the fourth quarter. The candidate was co-developed with Hanmi Pharmaceutical and licensed to BioMarin in a deal worth up to KRW 634.7 billion. Global Phase 1/2 trials are under way.
For investors, the earnings picture combines improving product mix and U.S. demand with transaction effects and continued development spending. The next results will show how much of the operating improvement persists after the seasonal flu contribution and the one-time items.
Specialist biopharma platform
GC Biopharma is a South Korean pharmaceutical company based in Yongin that produces and distributes blood-related treatments, vaccines, general medicines and non-prescription products. Its portfolio includes plasma-derived therapies, immunoglobulin products, influenza vaccines and treatments for rare diseases. The company holds a specialized position in South Korea's biopharmaceutical market while expanding selected products into the United States and other international markets.
GC Biopharma at a glance
- Company: GC Biopharma Corp.
- ISIN: KR7006280002
- Ticker: 006280
- Sector: Healthcare
- Industry: Medical - Pharmaceuticals
- Headquarters: Yongin, South Korea
- Third-quarter revenue: KRW 522.1 billion
- Third-quarter operating profit: KRW 49.2 billion, up 68.5 percent year over year
The KOSPI is the relevant benchmark for South Korean equities.
